NONOMURA; Kazuhiko

Patent Applications and Registrations

Patent applications and USPTO patent grants for NONOMURA; Kazuhiko.The latest application filed is for "selective ep4 receptor antagonistic substance for treatment of cancer".

Company Profile

0.14.14

NONOMURA; Kazuhiko - Aichi JP
NONOMURA; Kazuhiko - Shizuoka JP
Nonomura; Kazuhiko - Ibaraki Pref. JP
NONOMURA; Kazuhiko - Tsukuba-shi JP
Nonomura; Kazuhiko - Tsukuba JP
Nonomura; Kazuhiko - Ibaraki JP

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Selective Ep4 Receptor Antagonistic Substance For Treatment Of Cancer App 20220073510 - TAKE; Yukinori ; et al.	2022-03-10
Ghrelin Receptor Agonist For Treatment Of Cachexia App 20210179613 - SHIMADA; Kaoru ; et al.	2021-06-17
Ghrelin receptor agonist for treatment of cachexia Grant 10,975,070 - Shimada , et al. April 13, 2	2021-04-13
Selective EP4 receptor antagonistic substance for treatment of cancer Grant 10,947,235 - Take , et al. March 16, 2	2021-03-16
Selective Ep4 Receptor Antagonistic Substance For Treatment Of Cancer App 20200188367 - TAKE; Yukinori ; et al.	2020-06-18
Selective EP4 receptor antagonistic substance for treatment of cancer Grant 10,611,761 - Take , et al.	2020-04-07
Method Of Treating Atherosclerosis In High Triglyceride Subjects App 20180153861 - ARAI; Yoshie ; et al.	2018-06-07
Method of treating atherosclerosis in high triglyceride subjects Grant 9,867,811 - Arai , et al. January 16, 2	2018-01-16
Selective Ep4 Receptor Antagonistic Substance For Treatment Of Cancer App 20170253595 - TAKE; Yukinori ; et al.	2017-09-07
Selective EP4 receptor antagonistic substance for treatment of cancer Grant 9,688,674 - Take , et al. June 27, 2	2017-06-27
Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases Grant 9,457,084 - Kanazawa , et al. October 4, 2	2016-10-04
Selective Ep4 Receptor Antagonistic Substance For Treatment Of Cancer App 20150111920 - TAKE; Yukinori ; et al.	2015-04-23
Selective EP4 receptor antagonistic substance for treatment of cancer Grant 8,921,391 - Take , et al. December 30, 2	2014-12-30
Method Of Treating Atherosclerosis In High Triglyceride Subjects App 20140134262 - Arai; Yoshie ; et al.	2014-05-15
2,4- Diaminopyrimidine Derivatives App 20130345180 - BAENTELI; Rolf ; et al.	2013-12-26
2,4-diaminopyrimidine derivatives Grant 8,431,589 - Baenteli , et al. April 30, 2	2013-04-30
Ghrelin Receptor Agonist For Treatment Of Cachexia App 20120322821 - Shimada; Kaoru ; et al.	2012-12-20
Use Of Ep4 Receptor Antagonists In The Treatment Of Il-23 Mediated Diseases App 20120316197 - Kanazawa; Kiyoshi ; et al.	2012-12-13
Selective Ep4 Receptor Agonistic Substance For Treatment Of Cancer App 20120088723 - Take; Yukinori ; et al.	2012-04-12
2,4- Diaminopyrimidine Derivatives App 20110172231 - BAENTELI; Rolf ; et al.	2011-07-14
2,4-diaminopyrimidine derivatives Grant 7,943,627 - Baenteli , et al. May 17, 2	2011-05-17
2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof App 20060247251 - Buxton; Francis Paul ; et al.	2006-11-02
Pyrimidine derivaties App 20060100227 - Baenteli; Rolf ; et al.	2006-05-11

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.